Zydus, a leading discovery based global pharmaceutical company, has entered into a licensing agreement with China Medical System Holdings Limited (CMS) for the development and commercialisation of Desidustat, a novel oral HIF-PH inhibitor for the treatment of anaemia in patients with chronic kidney disease (CKD) not-on-dialysis and for the treatment of anaemia CKD patients on dialysis in Greater China. It has been reported that more than 120 million people are estimated to be living with CKD in China. CKD is a serious medical condition which is an unmet healthcare need involving gradual loss of functioning of kidneys eventually leading to kidney failure. If kidneys are healthy they will naturally secrete beneficial levels of a hormone called erythropoietin (EPO), which encourages red blood cell production that carry oxygen to the muscles and brain. If the kidneys are impaired they will produce reduced levels or tire of EPO production completely, leading to fatigue and anaemia. Anaemia is one of the frequent complications of CKD. A survey in China showed that the prevalence of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively. The target-achieving rate was only 8.2% for anaemia patients in non-dialysis CKD and 35.2% for dialysis CKD, showing unmet healthcare need. Speaking on the development, Pankaj R. Patel, chairman, Zydus Group said, “The licensing agreement with CMS will facilitate the development and commercialisation of Desidustat in Greater China, and make this innovative candidate available to millions of CKD patients living with anaemia.” Under the license agreement, CMS will pay Zydus an initial upfront payment, regulatory milestones, sales milestones and royalties on net sales of the product. The commercial terms of the license agreement are confidential. CMS will be responsible for development, registration and commercialisation of Desidustat in Greater China.